Aelix Therapeutics Is A Clinical Stage Biotechnology Company Based In Barcelonaspainfocused On Developing Therapeutic Vaccines For Hivfounded In 2014 As A Spin Off From The Hivacat Consortiumaelix Aims To Advance Strategies For Curing Hiv Through Innovative Immunogen Based Approaches The Company Is Working On Several Key Productsincluding The Hti Immunogenwhich Targets Specific Regions Of The Hiv Virus To Enhance Immune Responsesaelix Is Also Developing Vesatolimoda Small Molecule Immunostimulant That Is Tested In Combination With Hti Vaccines To Boost Antiviral Immunitycurrentlyaelix Is Conducting Phase 2 Clinical Trials For These Vaccinescollaborating With Partners Like Gilead Sciences With A Small Team Of Around Seven Employeesaelix Is Dedicated To Positioning Its Hti Vaccines As Essential Components Of Hiv Cure Regimenspotentially Reducing The Need For Lifelong Antiretroviral Therapythe Company Leverages Its Research Legacy From The Hivacat Consortium To Drive Its Mission Forward
